Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trialRUSSELL, Stuart D; SELARU, Paulina; PYNE, David A et al.The American heart journal. 2003, Vol 145, Num 1, pp 179-186, issn 0002-8703, 8 p.Article

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteersPITHAVALA, Yazdi K; YING CHEN; TORTORICI, Michael A et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 1, pp 103-112, issn 0344-5704, 10 p.Article

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small-Cell Lung CancerSOCINSKI, Mark A; NOVELLA, Silvia; TYE, Lesley et al.Journal of clinical oncology. 2008, Vol 26, Num 4, pp 650-656, issn 0732-183X, 7 p.Article

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non―Small-Cell Lung Cancer: A Phase III TrialSCAGLIOTTI, Giorgio V; KRZAKOWSKI, Maciej; PAPAI, Zsolt S et al.Journal of clinical oncology. 2012, Vol 30, Num 17, pp 2070-2078, issn 0732-183X, 9 p.Article

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancerGERVAIS, Radj; HAINSWORTH, John D; SELARU, Paulina et al.Lung cancer. 2011, Vol 74, Num 3, pp 474-480, issn 0169-5002, 7 p.Article

Acute hemodynamic effects of conivaptan, a dual V_1A and V₂ vasopressin receptor antagonist, in patients with advanced Heart failureUDELSON, James E; SMITH, William B; KONSTAM, Marvin A et al.Circulation (New York, N.Y.). 2001, Vol 104, Num 20, pp 2417-2423, issn 0009-7322Article